|
Canada-QC-CHATEAUGUAY कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- ASCO 2025 – Enhertu mounts its first-line charge
AstraZeneca and Daiichi Sankyo’s HER2-targeting ADC Enhertu, which made $3 8bn in 2024, could soon be heading for first-line breast cancer, following positive data presented at ASCO on Monday from the Destiny-Breast09 trial
- Enhertu Scores as First Line Therapy in HER2-Positive Breast . . .
Enhertu was first developed by Daiichi Sankyo as a HER2-directed ADC therapy, combining the monoclonal antibody trastuzumab with a topoisomerase I inhibitor AstraZeneca partnered with the Japanese pharma company to co-develop and commercialize Enhertu globally in 2019
- Enhertu plus pertuzumab reduced the risk of disease . . .
With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and are exploring its potential in earlier lines of treatment and in new breast cancer settings
- Enhertu Combo May Offer Longer Control for HER2+ Breast Cancer
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows A potential new first-line treatment option for patients with metastatic HER2-positive breast cancer was highlighted by Dr Sara M Tolaney during the 2025 ASCO Annual Meeting
- Enhertu Shows Promise as First-Line Treatment for Metastatic . . .
A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive metastatic breast cancer, early results show
- Enhertu drives highly significant efficacy in first-line . . .
AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab . . .
Ken Takeshita, Global Head, R D, Daiichi Sankyo, said: “ENHERTU continues to transform the treatment of metastatic breast cancer with the first new data in more than a decade to demonstrate improved outcomes for a broad population of patients with HER2-positive disease compared to THP in the first-line setting
|
|